Bard boosts investment in percutaneous transluminal endomyocardial revascularisation (PTER) company:
This article was originally published in Clinica
CR Bard has increased its investment in CorMedica, a US company developing systems for catheter-based percutaneous transluminal endomyocardial revascularisation (PTER). In March Bard secured exclusive worldwide distribution rights to eventual commercial products. Bard claims that PTER is a less-invasive technology that TMR and that CorMedica has a proprietary catheter tracking and navigation system.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.